GSK has entered into a strategic licensing agreement with China’s Jiangsu Hengrui Pharmaceuticals to develop up to 12 medicines across the areas of respiratory, immunology and oncology. Through the deal, valued at up to US$12 B, GSK gains exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to HRS-9821, a phosphodiesterase 3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD), including those who face continued dyspnoea.